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Although the pathogenesis of psoriasis is still a matter of 
oebate, there are several lines of evidence supporting the 
concept of this disease being immunologically mediated with 
r cells playing a crucial role. Because a cOllSiderable portion 
of the cellular infiltrate in psoriasis consists of activated T-
pelper cell.s, expression of HLA class 11 at;tigens .might be of 
f rticular lmportance for the understandmg of Its rathoge-
~esis. Therefore, we investigated the HLA type 0 patients 
with type I (early onset, positive family history) and type II 
Qate onset, no family history) psoriasis by means of serology 
((1 = 89) and genotyping using s.equence~specific oligonu-
leotide probes (n = 64). Serologic analYSIS of class I docu-~ented the association of type I psoriasis with HLA-Cw6, 
,1113, and -B57, whereas type II psoriasis showed a weaker 
correlation with HLA-Cw2 and -B27. Genotyping using 
SSO for class II detected the elevation of the HLA-
ORB1 *0701/2 allele frequency from 13% in normal popula-
tion to 36% in type I, but only to 15% in type II psoriatics. 
Moreover, positive correlations with type I psoriasis were 
detected for HLA-DQAl *0201 and HLA-DQBl *0303. 
The HLA-DRB1 *0701/2, -OQA1 *0201, -OQB1 *030~ e:c-
tended haplotype was found exclusively in type I psonaSlS. 
This is the first report documenting the association of distinct 
HLA class II alleles with type I psoriasis as detected on t~e 
DNA level, an approach both more specific and more sensi-
tive when compared to serology.] Invest DermatoI100:749-
752,1993 
~------------------------------------------------------------------------------------------------------
Psoriasis is a chronic hyperproliferative inflammatory disease affecting about 2% of Caucasians. Among the characteristic histologic features are epidermal hyper-proliferation and infiltration of both dermis and epider-mis by inflammatory cells including neutrophils, lym-hocytes, macrophages, and mast cells [1). 
r Although the pathogenesis of psoriasis is still a matter of discus-
ion, its association with distinct human leukocyte antigens (HLAs) ~ one feature psoriasis has in common with most autoimmune dis-
¢ cs studied so far [2-4J and thus supports the concept of psoriasis 
being a T -cell- mediated autoimmune disease .[5,6]. Based on this 
~LA association two types.of psonaSIS can be dlffe~ent1ated: type I, 
iJl2nifesting itself early 10 li fe and frequently affecting other family 
JIIcmbers, is associated with HLA-Cw6 (73.8% versus 20.4% in 
~ormals), -B 13 (34.3% versus 12.3%), and -Bw57 (29.7% versus 
6.2%). Type II with a significantly lat~r onset and lack of positive 
I ~mily history shows a weaker correlation With HLA-Cw2 (27.3% 
fCfSUS 5.5%) and -B27 (25.8% versus 10.1 %) [7,8] . 
The primary physiologic role of HLAs in the activity of the 
tnature immune system is sampling of peptides derived from the 
extracellular and intracellular protein pools by class II and class I 
molecules, respectively, for display in a multivalent form on the 
surface of the cell [9,10). These complexes are then available for 
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interaction with the clonally distributed ap receptors of CD4 + and 
CD8+ T cells, allowing the initiation of antigen-specific T-cell 
immune responses. HLA class II molecules are encoded in the HLA-
D region on the short arm of chromosome 6 [111. This region is 
subdivided into three subregions, HLA-DR, -DQ, and -DP. All 
subregions contain one functional expressed A gene (DRA1, 
DQA1, and DPA, respectively). HLA-DQ and -DP have also one B 
gene (DQBl and DPB1), whereas several B genes are contained 
within DR (Bl, B3 , B4, and B5). All genes encoding class II mole-
cules with the exception ofDRAl and DPAl are highly polymor-
phic with the variability localized to the second exon encoding the 
amino-terminal extracellular domain (12,131. 
Because the majority of T cells in the psoriatic infiltrate belongs 
to the CD4+ subset [14,15) and thus recognizes antigens in the 
context of class II molecules, data concerning association of these 
molecules with both types of psoriasis might be of particular impor-
tance for understanding the pathogenesis of this disease. We ther~­
fore analyzed the HLA types of patients with chronic stable psonas~s 
by means of serology (n = 89) and hybridization with speCific ~II­
gonucleotides (n = 64). Our results document a strong correlatIOn 
of type I but not type II psoriasis with HLA-DRB1 *0701/2, HLA-
DQA1*0201, and HLA-DQB1 *0303. 
MATERIALS AND METHODS 
Patients and HLA-Typing of Class I Antigens Eighty-nine 
patients with chronic stable psoriasis from the Departmen~ of Der-
matology, University of Ulm, and the Dermatology ChmcBad 
Bentheim, FRG, were assigned to either type I or type II psonasls. 
Sixty patients with positive famil), histoty and onset not later th~n at 
the age of 30 were grouped to type I psoriasis; 29 patients WIth a 
0022-202X/93/S06.00 Copyright © 1993 by The Society for Investigative Dermatology, Inc. 
749 
750 SCHMITT-EGENOLF ET AL 
Table I. Frequencies' of DRB1, DQA1, and DQB1 Alleles 
Differing Significantly in Chromosomes of Patients with Type I 
or Type II Psoriasis and Controls [16] 
HLA Allele Controlb Type I' Type nJ 
DHRB1 *0701/02 
DQA1*0201 
DQB1*0303 
35 (13.2) 
35 (13.2) 
15 (5 .7) 
34 (36.2)' 
35 (37.2)' 
20 (21.3)' 
5 (14.7) 
5 (14.7) 
o 
• Each column gives the absolute numbers and. in brackets. the percentage. 
, 265 chromosomes tested. 
, 94 chromosomes tested . 
J 34 chromosomes tested. 
, Statistically significant (p < 0.0001) . 
negative family history and onset later than age of 40 were regarded 
as suffering from type II psoriasis. Data obtained by Begovich et at 
[16] served as control. The genetic characteristics of the population 
studied by Begovich et al are comparable to the population in 
Northern Europe [17]. Analysis ofHLA class I molecules was done 
by means of standard serologic methods [18]. 
Polymerase Chain Reaction and Gel Electrophoresis Poly-
merase chain reaction (PCR) was essentially done as previously 
described [19] with the following modifications. For generic am-
plification of 286-bp fragments of DRB second exon AMPl 
5'-TTCGCCGCTGCACTGTGAAGCTCTC and AMP3 
5'-CCGAATCCTTCGTGTCCCCACAGCCG were used as 
primers. After 30 cycles of PCR with 2.5 units of Thermos aquati-
cus DNA polymerase (Cetus/Perkin Elmer) products were checked 
for single-band amplimers on ethidium bromide- stained minigels. 
After heat denaturation of the DNA, aliquots were spotted manu-
ally on nylon membranes and immobilized by ultraviolet irradiation 
(120 m], Stratalinker, Stratagene). 
Sequence-Specific Oligonucleotides and Hybridization 
Conditions The oligonucleotides were made on an Applied Bio-
systems 380B DNA synthesizer and have been described elsewhere 
[20]. Each sequence-specific oligonucleotide was 3'-end labeled by 
terminal polynucleotidyl transferase (Boehringer Mannheim) with 
dideoxy-digoxigenin. Filters were pre-hybridized in a solution that 
contains 3 M tetramethylammonium chloride, 100,ug/ml salmon 
sperm DNA, 50 mM Tris-HCl, 0.1 % sodium dodecylsulfate, 5 X 
Denhards solution and 2 mM ethylenediaminetetraacetic acid for 
2 h, then 3 - 5 pM labeled sequence-specific oligonucleotides 
probes were added and hybridization continued for at least 3 h . 
After removal of the hybridization solution, filters were washed 
under stringent conditions in a buffer containing 3 M tetramethyl-
ammonium chloride, 50 mM Tris-HCI, and 0.2% sodium dodecyl-
su lfate. Hybridized oligonucleotides were detected using a di-
goxygenin-specific monoclonal antibody conjugated to alkaline 
phosphatase (Boehringer Mannheim) and binding was visualized 
with chemiluminescence substrate (ECL, Amersham) by autoradi-
ography. 
Statistical Evaluation Absolute numbers of chromosomes posi-
tive for the alleles under investigation were determined and percent-
ages were calculated. For those alleles where clear differences were 
observed compared to the control population chi square tests of 
homogeneity were performed. In cases with a p value less than 
0.0001 the observed difference was rated as statistically significant 
(Table I) . 
RESULTS 
Patient Groups Based on the anamnestic data, 60 of the 89 pa-
tients were grouped to type I psoriasis whereas 29 patients were 
regarded as type II psoriatics (data not shown). Although classifica-
tion was done according to patient history, subsequent HLA class I 
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typing showed the well-established pattern (see below), thus under-
linil1:g .the validity of these informations for the classification of 
pSOriaSIs. 
HLA Class I Typing by Serology Analysis for class I molecules 
was done serologically (n = 89) and revealed a frequency of83% for 
Cw6 in type I psoriatics (data not shown). B13 was found in 18% 
and B57 in 55%. In type II psoriasis, we observed 38% positive for 
Cw6; the percentages for B13 and BS7 were 17% and 7%, respec-
tively. These frequencies are much closer to those seen in normals, 
where the respective numbers are 16.5%, 5.7%, and 5.7%. 
HLA-DRB1 *0701/02 Is Associated with Type IbutNotType 
II Psoriasis Expression of HLA class II molecules was examined 
by the use of sequence-specific oligonucleotides in 64 patients, 47 
type I and 17 type II psoriatics. Twenty D RB 1 alleles were found in 
the patients analyzed (DRB1 *0101/02, -*1501, -*1502, -*1601, 
-*0301, -*0401, -*0402, -*0403, -*0404, -*0408, -*1101, -*1103, 
-*1104, -*1201, -*1301, -*1302, -*1303, -*1401, -*0701 /02, 
-*0801). 
The allele most frequently detected was HLA-DRB1 *0701/02. 
This allele was present in 28 patients (60%) with type I psoriasis; six 
of them were homozygous. In contrast, only five type II psoriatics 
(29%) were positive for this allele, none of them being homozy-
gous. At the chromosomal level , the numbers were 34 (36%) in type 
I and five (15%) in type II psoriatics compared to 13% in the control 
population (Table I). These differences in frequency are statistically 
significant (p < 0.0001) as confirmed by the chi-square test of ho-
mogeneity. All other DRBl alleles tested showed no significant 
difference. 
HLA-DQA1*0201 as Well as -DQB1*0303 Are Significantly 
Increased in Type I Psoriasis Seven DQAl (DQAl *0101 , 
-*0102, -*0103, -*0201, -*0301, -0401 *, -*0501), and 11 DQBl 
(DQB 1 *201, -*301, -*302, -*303, -*501, -*502, -*503, -*601 , 
-*602, -*603, -*604) alleles were detectable in our patients. The 
only statistically significant difference observed was the elevation of 
HLA-DQA1*0201 and -DQBl *0303 in type I psoriasis. Twenty-
nine type I psoriatics were DQA1*0201 positive, representing 62% 
of the patients with type I psoriasis, whereas only five type II psoriat-
ics (29%) had this allele. The corresponding numbers at the DNA 
level were 35 (37%) and five (15%), respectively. In the control 
population, 13% of the chromosomes were found to be positive for 
this allele (Table I). Some alleles, e.g., DQA1*0103, were found to 
be considerably more frequent in type II compared to type I psoria-
sis. However, in the case ofDQAl *0103 the p value was 0.0058 and 
the increase therefore not considered statistically significant. 
The most pronounced correlation of a DQB 1 allele with either 
type of psoriasis was noted for DQBl *0303, which was present in 
18 individuals, all of them type I psoriatics representing 38% of all 
patients in this group. The genetic frequency was calculated to 21 %. 
This value, too, reached significance when compared to the fre-
quency of 5.7% observed in the control population (Table I). 
Extended Haplotype HLA-DRB1 *0701/2, -DQA1 *0201, 
-DQB1*0303 Is Exclusively Found in Type I Psoriasis Be-
sides the association of individual alleles with both types of psoriasis 
we also investigated the frequencies of important extended haplo-
types in either type. Due to linkage disequilibrium in HLA, 
DRBl *0701 is associated with DQAl *0201. These two alleles 
form an extended haplotype with DQB 1 *0201 or, more rarely, 
with DQBl *0303. Interestingly, the rare extended haplotype con-
sisting of alleles HLA-DRB1*0701/2, DQA1*0201, and 
DQBl *0303 was found on 20 chromosomes in 18 individuals with 
type I psoriasis; thus it was present in 38% of type I psoriatics . In 
contrast, this haplotype was not detectable in type II psoriatics. On 
the other hand, HLA-DRB1*0701/2 association with HLA-
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Table II. Percentage of Patients with Type I or Type II 
Psoriasis Exhibiting One of Two Extended Haplotypes 
Containing HLA-DRBl *0701/2 
:ype I 
:ype II 
HLA-DRB1*0701/2 HLA-DRB1 *0701/2 
and HLA-DQB1*0201 and HLA-DQB1 *0303 
10.6 
23.5 
38.3 
0.0 
DQB 1*0201 was found in 24% of type II psoriatics and 11 % of type 
I psoriatics (Table II). 
DISCUSSION 
Although the pathogenesis of psoriasis is still a matter of debate, 
Ihere is accumulating evidence for the concept of psoriasis being an 
lutoimmune disease with T cells playing an important role: besides 
macrophages, they account for the majority of the mononuclear 
infil trate [14,21). Most of them belong to the CD4 + subset [15) and 
express activation markers [14,15,22) . A number of proteins abnor-
mally expressed on the surface of keratinocytes in psoriatic epider-
mis is known to be inducible by cytokine secretion of T cells 
123,24]. Finally, several therapeutic approaches using T -cell-
suppressive agents have been proved to be effective [25 - 27). Thus, 
if the hypothesis of the T -cell- mediated autoimmune pathogenesis 
was true, data on the expression ofHLA class II molecules are crucial 
10 understand the pathomechanisms underlying this disease, be-
cause it is class II rather than class I molecules that present pep tides 
10 CD4 + cells. 
The peR made it possible to identify nucleotide sequence varia-
tions directly at the genomic level using sequence-specific oligonu-
cleotide probes for DNA hybridization [28,29) . Genotyping re-
vealed a significantly higher degree of class II polymorphism than 
defined by other methods [30). Thus, PCR-based oligonucleotide 
typing is a powerful method of defining HLA polymorphism, 
which proves superior to other techniques. This is particularly true 
in comparison to serologic approaches to define class II polymor-
phism. 
Attempts to correlate HLA type and susceptibility to £soriasis 
often focused on the association with class I molecules [7,8,31], 
although an increased frequency of HLA-DR7 has been noted as 
early as 1979 [32] and since then has repeatedly been confirmed 
133). Sakkas et af were able to define HLA-DR7a as an important 
lusceptibility factor for psoriasis and psoriatic arthritis [34) . Our 
data, too, document this HLA-DR7 correlation and extend it inso-
far as we were able to show that this correlation holds true only for 
type I but not for type II psoriasis (Table I). Consistent with our 
findings are preliminary data by Henseler (Henseler, personal com-
munication). Interestingly, he found 100% of type I psoriatics posi-
tive for HLA-DR7, whereas only 33% of the type II psoriatics 
expressed this molecule. In contrast, we observed HLA-
DRB1*0701/2 only in 60% of patients with type I psoriasis. In case 
of type II psoriasis, our numbers equal those of Hen seier. One expla-
nation might be the inferior specificity of serologic phenotyping 
versus genotyping, particularly in the case of class II typing. 
Besides HLA-DRBl *0701/02, alleles HLA-DQA 1*0201 and 
HLA-DQBl *0303 showed a significantly higher correlation with 
type I psoriasis (Table I). Not only the association of distinct HLA 
class II alleles with type I psoriasis is remarkable, but also the associa-
tion of these HLA class II alleles with each other. Yunis et af identi-
fied two extended haplotypes involving HLA-DRBl *0701/2: this 
allele was found to be associated either with DQw2 and the 
DQB 1 *0201 allele or with DQw9 and the DQB 1*0303 allele [35)' 
the latter haplotype being less frequent [36]. Due to linkage disequi-
librium in HLA, DRBl *0701/2 is associated with DQAl*0201, 
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which therefore is part of both haplotypes . To our knowledge, only 
the former type has been found to show association with certain 
diseases [37] . Thus, it is interesting to note that in type I psoriatics 
the rare haplotype consisting of HLA-DRBI *0701/2 and HLA-
DQB 1 *0303 was found to be more than three times as frequent as 
the HLA-DRBl *0701/2, -DQBl *0201 haplotype. In contrast, 
this rare haplotype does not appear at all in type II psoriasis (Table 
II). These data might point towards HLA-DQB as a major suscepti-
bility antigen for type I psoriasis. 
Only rarely, a clear increase in the frequency of a class II allele was 
observed in type II psoriasis versus type I and the control population. 
One example is DQAl*0103. The p value was 0.058 for this in-
crease and thus did not reach statistical significance. Thus, a possible 
association of type II psoriasis with certain class II molecules should 
nor-be excluded on the basis of these data. However, our data make it 
extremely unlikely that type I and type II psoriasis show associations 
with similar HLA class II molecules. Therefore, if antigens are 
involved in their respective pathogenesis, exclusive sets of antigens 
might exist for both types to trigger a T-helper-cell-mediated au-
toimmune reaction . 
To summarize, this is the first report demonstrating the correla-
tion of several HLA-DR and -DQ molecules with type I psoriasis at 
the genomic level. Association with class II molecules further sup-
ports the concept of type I psoriasis being a T -cell- mediated au-
toimmune disease. 
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